Related references
Note: Only part of the references are listed.Training Needs of Clinical and Research Professionals to Optimize Minority Recruitment and Retention in Cancer Clinical Trials
Soumya J. Niranjan et al.
JOURNAL OF CANCER EDUCATION (2019)
New clinical trial designs in the era of precision medicine
Elena Garralda et al.
MOLECULAR ONCOLOGY (2019)
Novel therapies in low- and high-risk myelodysplastic syndrome
Ulrich Germing et al.
EXPERT REVIEW OF HEMATOLOGY (2019)
Representation of therapy-related myelodysplastic syndrome in clinical trials over the past 20 years
Uma Borate et al.
BLOOD ADVANCES (2019)
Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies
Abby Statler et al.
BLOOD (2018)
Social factors matter in cancer risk and survivorship
Lorraine T. Dean et al.
CANCER CAUSES & CONTROL (2018)
Patient Enrichment for Precision-Based Cancer Clinical Trials: Using Prospective Cohort Surveillance as an Approach to Improve Clinical Trials
William S. Dalton et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Clinical trials recruitment planning: A proposed framework from the Clinical Trials Transformation Initiative
Grant D. Huang et al.
CONTEMPORARY CLINICAL TRIALS (2018)
H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers
Michael Seiler et al.
NATURE MEDICINE (2018)
At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical Trials
Hala T. Borno et al.
ONCOLOGIST (2018)
Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions
David P. Steensma et al.
CANCER (2018)
Accrual to Clinical Trials (ACT): A Clinical and Translational Science Award Consortium Network
Shyam Visweswaran et al.
JAMIA OPEN (2018)
Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation
Amer M. Zeidan et al.
BLOOD (2018)
Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples
L. A. Renfro et al.
ANNALS OF ONCOLOGY (2017)
Myelodysplastic Syndromes, Version 2.2017 Clinical Practice Guidelines in Oncology
Peter L. Greenberg et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
A Call for Action: Increasing Enrollment of Untreated Patients With Higher-Risk Myelodysplastic Syndromes in First-Line Clinical Trials
Amer M. Zeidan et al.
CANCER (2017)
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides
A. M. Zeidan et al.
LEUKEMIA (2016)
Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study
Rena Buckstein et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes
Amer M. Zeidan et al.
CANCER (2016)
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry
T. Bernal et al.
LEUKEMIA (2015)
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)
M. G. Della Porta et al.
LEUKEMIA (2015)
Incidence and Burden of the Myelodysplastic Syndromes
Christopher R. Cogle
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2015)
Unsuccessful trial accrual and human subjects protections: An empirical analysis of recently closed trials
Benjamin Carlisle et al.
CLINICAL TRIALS (2015)
Adherence and Retention in Clinical Trials: A Community-Based Approach
Mona N. Fouad et al.
CANCER (2014)
Overview of EMPaCT and Fundamental Issues Affecting Minority Participation in Cancer Clinical Trials: Enhancing Minority Participation in Clinical Trials ( EMPaCT): Laying the Groundwork for Improving Minority Clinical Trial Accrual
Selwyn M. Vickers et al.
CANCER (2014)
State- of- the- Science of Patient Navigation as a Strategy for Enhancing Minority Clinical Trial Accrual
Rahel G. Ghebre et al.
CANCER (2014)
Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia
Regina Garcia-Delgado et al.
LEUKEMIA RESEARCH (2014)
Methods to improve recruitment to randomised controlled trials: Cochrane systematic review and meta-analysis
Shaun Treweek et al.
BMJ OPEN (2013)
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Pierre Fenaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Biomarker-Driven Early Clinical Trials in Oncology A Paradigm Shift in Drug Development
Daniel S. W. Tan et al.
CANCER JOURNAL (2009)
Therapy-related myeloid neoplasms
Richard A. Larson
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Share Paper
